Small-cap pharmaceutical company (market cap ₹236.59 Cr) with quarterly standalone revenues of ₹2.93–₹8.2 Cr. Profitability erratic until recent recovery; dividend paid Sep 2025.
Face value
₹10
Market cap
₹203 Cr
P/E
143.1×
P/B
4.2×
Dividend yield
0.3%
ROE
16%
ROCE
19.3%
Debt / equity
0.19
OPM
14.5%
EPS (TTM)
₹1.2
Book value
₹39.4
52-week high
₹239.7
52-week low
Key insights
Company research notes and source-linked reviews
Key risks
PE ratio 166.73 is extreme—verify if current earnings are unusually depressed or growth expectations are misaligned with fundamentals.
Quarterly revenue volatile (₹2.93–₹8.2 Cr range) with losses in five of eight quarters (2019–20)—understand causes of earnings lumpiness and sustainability.
1y return –13.08% against 52w high ₹254 shows recent underperformance—verify if operational deterioration or market repricing.
Zero FII ownership despite ROE 24.59% suggests institutional caution—identify what concerns large investors.
Generated analysis · source review pending
Growth drivers
Operating margin recovered from –11.27% (Dec 2019) to 20.27% (Mar 2021)—verify what drove operational efficiency gains.
Revenue recovered from ₹2.93 Cr (Dec 2019) to ₹7–8 Cr range (2020–21)—check sustainability and whether from organic growth or lumpy contracts.
ROE 24.59% shows capital deployed efficiently; verify whether earnings can sustain this return as company scales.
D/E 0.15 is low, providing capacity for capex or acquisitions if pursued—verify management's capital allocation strategy.
Generated analysis · source review pending
₹165.1-28.8%1Y
Beta
0.91
Moves with the index
Volatility (1y)
54.3%
Annualised, daily returns
RSI (14)
25.2
Oversold territory
Rel. strength (1y)
-39.9%
Behind the market
Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.
Quick read
rule-based
Pros
+Strong return on equity of 20.9% (3-yr avg)
+High return on capital employed of 25.1%
+Profit CAGR of 37.3% over the last 5 years
+Revenue CAGR of 20.9% over the last 5 years
+Comfortable interest coverage of 18.1×
+Dividend payout of 43.3% of profit
Cons
−Expensive at 143.1× trailing earnings
Research score
Structured signal from quality, growth, valuation and momentum.
46/100
Business quality
63
Growth
80
Revenue & net profit
₹ crore, by fiscal year
RevenuePAT
Margins
% of revenue, by fiscal year
OPMPAT margin
Peers
Comparable companies from the narrowest available industry classification.
Loading peers…
Financials
Reported profit and loss, balance sheet, cash flow and growth history.
Loading financials…
Ratios
Annual operating, return, leverage and working-capital ratios.
Loading ratios…
Shareholding
Quarterly ownership, named holders, insider transactions and disclosed deals.
Loading shareholding…
F&O
Current futures and options contracts with compact option-chain pages.
Loading f&o…
Fund holders
Mutual-fund schemes that disclosed a holding in the company.
Loading fund holders…
Documents
Annual reports, exchange filings, offer documents, ratings and earnings-call material.
Loading documents…
Events
Upcoming dates and the company’s corporate-action history.
Loading events…
Announcements
Latest exchange announcements, filings and downloadable documents.
Loading announcements…
₹129.3
Valuation
18
Momentum
22
1
Dividend dividend19 Sept 2025 · ex-date₹0.5
1
Board meeting to consider results14 Aug 2026
Not in the F&O segment
Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.
Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.
No fund holdings on record
No scheme among the 32 fund houses on record reported a position in Sanjivani Paranteral Ltd. Portfolios are published monthly by each AMC; coverage is still partial.
Documents link to external sources (exchange filings, company investor pages).
Promoter holding down 0.78 percentage points since Sep 2023.
16 deals · 12 Jan 2022 – 19 Feb 2025
Date
Client
Type
Venue
Side
Quantity
Price
Value
19 Feb 2025
MONIKA GARWARE
Bulk
BSE
Sell
2,27,509
₹243.44
₹5.54 Cr
26 Aug 2024
NEXT ORBIT VENTURES FUND
Bulk
BSE
Sell
2,00,000
₹290.00
₹5.80 Cr
22 Aug 2024
NEXT ORBIT VENTURES FUND
Bulk
BSE
Sell
1,00,000
₹280.46
₹2.80 Cr
20 Dec 2023
SUREKHA HARAN
Bulk
BSE
Sell
1,01,034
₹152.70
₹1.54 Cr
18 Sept 2023
SUREKHA HARAN
Bulk
BSE
Buy
50,000
₹100.05
₹0.50 Cr
15 Sept 2023
SETU SECURITIES PVT. LTD.
Bulk
BSE
Buy
50,000
₹100.06
₹0.50 Cr
12 Sept 2023
SUREKHA HARAN
Bulk
BSE
Buy
50,000
₹100.00
₹0.50 Cr
27 Mar 2023
WOODSTOCK SECURITIES PRIV ATE LTD
Bulk
BSE
Sell
55,966
₹27.02
₹0.15 Cr
24 Mar 2023
WOODSTOCK SECURITIES PRIV ATE LTD
Bulk
BSE
Sell
79,292
₹25.94
₹0.21 Cr
20 Mar 2023
NEXT ORBIT VENTURES FUND
Bulk
BSE
Sell
60,000
₹32.75
₹0.20 Cr
1–10 of 16
1 / 2
Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.
Mr. ASHWANI ANAMISHARAN KHEMKAExecutive Director-Chairperson-MD
Mr. SRIVARDHAN ASHWANI KHEMKAExecutive Director
Mrs. MONIKA AMIT SINGHANIANon-Executive - Independent Director
Mr. ABHAY MILAN SHAHNon-Executive - Independent Director
Mr. BASANT SHRIVASTAVANon-Executive - Independent Director
Mr. Pritesh JainChief Financial Officer
Mr. Ravikumar Venkatramuloo BogamCompany Secretary & Compliance Officer
Current officeholders as filed with BSE. A person holding two offices is listed once per office.
Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On Thursday, 21St May, 2026 Pursuant To Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results Along With Audit Report For The Fourth Quarter And Financial Year Ended 31St March, 2026
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A PDF
7 Apr 2026, 6:54 pmCompany Update
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF
Date
Category
Subject
Filing
15 May 2026, 3:20 pm
Board Meeting
Board Meeting Intimation for Intimation Of Notice Of Board Meeting To Be Held On Thursday, 21St May, 2026 Pursuant To Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results Along With Audit Report For The Fourth Quarter And Financial Year Ended 31St March, 2026